Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20372911 | 0.95 | TAS1R3 (0.40) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL19098841 | 0.92 | NR1I2 (0.38) | TAS1R3TAS1R1 | |
| SCHEMBL20091067 | 0.87 | CYP3A4 (0.39) | CYP3A4TSHRPPARGPPARDPPARA | |
| SCHEMBL21466452 | 0.87 | NR1I2 (0.41) | — | |
| SCHEMBL22350128 | 0.86 | TAS1R3 (0.50) | TAS1R3TAS1R1 | |
| SCHEMBL2499134 | 0.85 | GAA (0.52) | TAS1R3TAS1R1 | |
| SCHEMBL2497911 | 0.85 | GAA (0.52) | TAS1R3TAS1R1 | |
| SCHEMBL19098830 | 0.85 | NR1I2 (0.39) | TAS1R3TAS1R1PDE4D | |
| SCHEMBL18948447 | 0.85 | SMN1; SMN2 (0.40) | TAS1R3TAS1R1PDE4APDE4BPDE4C | |
| SCHEMBL22932925 | 0.84 | PPARG (0.50) | PDE4APDE4BPDE4CPDE4DPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189777-B2 | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-07-06 | — | — | US | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189777-B2 | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease | RORC, RORB, RORA | TAS1R3 1210/4885TAS1R1 1109/4885PDE4A 2552/4885 |
| US-20170190659-A1 | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | TAS1R3 1708/4885TAS1R1 1711/4885PDE4A 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.